World's Best Scientists 2026 revealed!
Martin J. van den Bent

Martin J. van den Bent

D-Index & Metrics

Medicine

D-Index
129
Citations
103861
World Ranking
2521
National Ranking
98

Martin J. van den Bent publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Martin J. van den Bent sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 675 publications — 79th percentile

79% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Martin J. van den Bent D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Martin J. van den Bent sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 129 D-Index — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Martin J. van den Bent is affiliated with Erasmus University Rotterdam in the Netherlands. Their research primarily focuses on medical fields, with a significant concentration on genetics, pulmonary and respiratory medicine, radiology, nuclear medicine and imaging, neurology, and molecular biology.

Their main topics of study cover glioma diagnosis and treatment, brain metastases and treatment, radiomics and machine learning in medical imaging, meningioma and schwannoma management, neuroblastoma research and treatments, medical imaging techniques and applications, and the use of MRI in cancer diagnosis.

The frequent publication venues for Martin J. van den Bent include Neuro-Oncology, Neuro-Oncology Advances, Journal of Clinical Oncology, The Lancet Oncology, and European Journal of Cancer.

Their body of work includes recent papers such as:

  • EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood (2020, Nature Reviews Clinical Oncology)
  • Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions (2020, Neuro-Oncology)
  • Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline (2021, Journal of Clinical Oncology)
  • Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (2023, New England Journal of Medicine)
  • EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours (2021, Annals of Oncology)

Collaborations are a notable part of their research practice, frequently working with coauthors such as Michael Weller, Patrick Y. Wen, Wolfgang Wick, Pim J. French, and Marion Smits.

Best Publications

  • Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

    Roger Stupp;Warren P. Mason;Martin J. van den Bent;Michael Weller

  • Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

    Roger Stupp;Monika E. Hegi;Warren P. Mason;Martin J. van den Bent

  • Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

    Patrick Y. Wen;David R. Macdonald;David A. Reardon;Timothy F. Cloughesy

  • Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

    Dieta Brandsma;Lukas Stalpers;Walter Taal;Peter Sminia

  • Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

    Martin J. van den Bent;Alba A. Brandes;Martin J.B. Taphoorn;Johan M. Kros

  • EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.

    Michael Weller;Martin van den Bent;Matthias Preusser;Emilie Le Rhun

  • Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma

    Francesco Pignatti;Martin van den Bent;Desmond Curran;Channa Debruyne

  • Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

    Roger Stupp;Roger Stupp;Monika E Hegi;Thierry Gorlia;Sara C Erridge

  • Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial

    Martin J. van den Bent;Antoine F. Carpentier;Alba A. Brandes;Marc Sanson

  • European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas

    Michael Weller;Martin van den Bent;Jörg C Tonn;Roger Stupp

  • Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

    Walter Taal;Hendrika M Oosterkamp;Annemiek M E Walenkamp;Hendrikus J Dubbink

  • Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma

    Lauren E. Abrey;Tracy T. Batchelor;Andrés J.M. Ferreri;Mary Gospodarowicz

  • Response assessment criteria for brain metastases: proposal from the RANO group

    Nancy U Lin;Eudocia Q Lee;Hidefumi Aoyama;Igor J Barani

  • Lomustine and Bevacizumab in Progressive Glioblastoma

    Wolfgang Wick;Thierry Gorlia;Martin Bendszus;Martin Taphoorn

  • MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

    Michael Weller;Roger Stupp;Guido Reifenberger;Alba A. Brandes

  • Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

    Patrick Y. Wen;Michael Weller;Eudocia Quant Lee;Brian M. Alexander

  • EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

    Michael Weller;Martin van den Bent;Kirsten Hopkins;Jörg C Tonn

  • Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology

    Lonneke A M Gravendeel;Mathilde C M Kouwenhoven;Olivier Gevaert;Johan J de Rooi

  • Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

    Martin J. van den Bent;Alba A. Brandes;Roy Rampling;Mathilde C.M. Kouwenhoven

  • Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial

    René Olivier Mirimanoff;Thierry Gorlia;Warren Mason;Martin J. Van Den Bent

Frequent Co-Authors

Michael Weller
Michael Weller University of Zurich
Johan M. Kros
Johan M. Kros Erasmus University Rotterdam
Wolfgang Wick
Wolfgang Wick German Cancer Research Center
Roger Stupp
Roger Stupp Northwestern University
Alba A. Brandes
Alba A. Brandes Institute of Neurological Sciences
Patrick Y. Wen
Patrick Y. Wen Harvard University
Michael A. Vogelbaum
Michael A. Vogelbaum Cleveland Clinic
Monika E. Hegi
Monika E. Hegi University of Lausanne
Pieter Wesseling
Pieter Wesseling University of Amsterdam
Marion Smits
Marion Smits Erasmus University Rotterdam

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career in the USA doesn’t always mean becoming a physician. There are many related online degrees and flexible career pathways in healthcare. For those interested in managing healthcare systems, a health administration degree can open doors to supervisory and leadership roles in hospitals and clinics.

Registered nurses seeking career advancement should consider adn to fnp programs, which enable nurses with an associate’s degree to move directly into family nurse practitioner positions through convenient online bridge programs.

Nutrition is another pathway with growing demand. Earning an online bachelor's in nutrition is ideal for those passionate about health promotion, dietary planning, and patient counseling.

For working professionals aiming for higher administrative roles, selecting whats the best online mha program for working adults can help balance career growth with a busy schedule, leading to executive opportunities in healthcare organizations.

These online options deliver flexibility, allowing you to advance your education and navigate diverse healthcare career paths on your own terms.

Best Scientists Citing Martin J. van den Bent

Trending Scientists

Recently Published Articles